Fed Pullback Pledge...
Health Care: Drugs
Achillion Pharmaceuticals Inc. (ACHN: NASDAQ)
$8.13 0.12 | 1.50%
06/19/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -47.13M | -44.21M | -25.48M | -25.93M |
| Operating Gains/Losses | 1.00K | -111.00K | 6.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -174.00K | 143.00K | -181.00K | -65.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -519.00K | 2.12M | 395.00K | -267.00K |
| (Decrease) Increase In Other Current Liabilities | 502.00K | 1.95M | -537.00K | 338.00K |
| (Increase) Decrease In Other Working Capital | -2.49M | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 3.18M | 3.00M | 2.32M | 2.01M |
| Net Cash From Continuing Operations | -46.53M | -35.56M | -23.89M | -22.31M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -46.53M | -35.56M | -23.89M | -22.31M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 85.05M | 0.00 | 9.55M | 31.40M |
| Purchases of Property, Plant & Equipment | -656.00K | -732.00K | -169.00K | -42.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -79.76M | -80.28M | -39.70M | -7.34M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 53.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 4.64M | -35.24M | -30.32M | 24.07M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 44.24M | 61.52M | 72.74M | 108.00K |
| Repayment of Long-Term Debt | -282.00K | -546.00K | -2.87M | -3.21M |
| Repurchase of Capital Stock | 0.00 | 146.00K | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 362.00K | 420.00K | 0.00 | 0.00 |
| Net Cash From Financing Activities | 44.32M | 61.54M | 69.87M | -3.10M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 2.42M | -9.26M | 15.66M | -1.35M |
Portfolios with ACHN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- UserMy Watch List
- ContributorStocks Under-$10 Setting Up...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Rising On Unusual Vo...
- UserThe cash burners
- ContributorStocks Under-$10 Moving Hig...
Latest ACHN Headlines from TheStreet
- 5 Stocks Seeing Bullish Options Activity 06.13.13 | 12:06 pm
- Achillion To Present At The Wells Fargo 2013 Healthcare Conference 06.12.13 | 06:06 am
- Biotech Stock Mailbag: 2013 Clinical Trials Calendar 06.07.13 | 07:06 am
- Achillion Pharmaceuticals (ACHN) Shares Cross Above 200 DMA 05.31.13 | 04:05 pm
- Achillion Nominates ACH-3422 As Nucleotide For The Treatment Of Chronic HCV 05.30.13 | 06:05 am
- Achillion Names Milind Deshpande, Ph.D., As President, Chief Executive Officer, Following Announced Retirement Of Michael Kishbauch 05.28.13 | 04:05 pm
- Achillion Appoints Dr. David Apelian As Chief Medical Officer And Expands Clinical Operations Team 05.15.13 | 06:05 am
- Achillion To Present At Three Upcoming Investor Conferences 05.09.13 | 06:05 am
- Achillion Reports First Quarter 2013 Financial Results 05.07.13 | 06:05 am
- Oversold Conditions For Achillion Pharmaceuticals 05.02.13 | 12:05 pm
Press Releases for ACHN
- Emerald Holds Annual Groundhog Day Investment Forum - Business Wire 02.06.12 | 08:02 am
Partner Headlines for ACHN
- Gilead Stock Hits New High As HCV Drug Keeps Rocking - Investor's Business Daily 02.19.13 | 04:02 pm
- New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3 - Seeking Alpha 11.30.12 | 08:11 am
- Cramer's Mad Money - 8 Things To Watch In The Week Ahead (9/28/12) - Seeking Alpha 09.30.12 | 07:09 am
- Achillion Pharma draws bullish bet - NASDAQ 09.25.12 | 04:09 pm
- 3 Stocks Upgraded On September 19 To Consider - Seeking Alpha 09.21.12 | 10:09 am
- Morning Market Movers - Benzinga 09.19.12 | 09:09 am
- REVEALED: New Analyst Stock Coverage to Assess Today - Wall St. Cheat Sheet 06.13.12 | 04:06 am
- Stock Insights: Achillion Pharmaceuticals, DG FastChannel, Tempur Pedic, Iron Mountain, Nasdaq OMX June 7th - Wall St. Cheat Sheet 06.07.12 | 10:06 am
- Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C - Benzinga 04.21.12 | 04:04 pm
- UPDATE: Bank of America Raises Actuant's PT - Benzinga 03.08.12 | 01:03 pm
